Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Composition and structure of nasopharyngeal microbiome relate to COVID-19 disease severity

Breathing treatments are provided to hospitalized COVID-19 patients. In this study, the researchers examined the community composition in relation to three attributes - COVID-19 status, breathing assistance, and antibiotic use. This study is published in the journal, Applied Microbiology.

12 Jul 2021

What is behind the inconsistent results of COVID-19 clinical trials?

“Most clinical studies of antiviral drugs for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have failed to observe a statistically significant effect, which may be due to poor designs of clinical trials.”

12 Jul 2021

SARS-CoV-2 mRNA vaccine efficacy reduced in patients with CD20-B-cell depleting treatment history

Researchers from Switzerland recently investigated humoral and cell-mediated immune responses to mRNA-based vaccines in patients undergoing treatment with CD20-B-cell depleting agents for autoimmune diseases, transplantation, or malignancy.

12 Jul 2021

Socioeconomic inequities and structural racism are neglected pieces of SARS-CoV-2 transmission networks

A recent perspective article published in the prestigious journal Science highlights how the use of network-driven strategies for adequately informing rapidly emergent epidemic responses is not only evidence-based but also an equitable way forward for the current coronavirus disease (COVID-19) pandemic and future respiratory pandemics.

12 Jul 2021

Accelerating the design of minibinder therapeutics resilient to SARS-CoV-2 mutations

Multivalent protein-based minibinders hold great promise as potential prophylactic and treatment agents, as they can retain their activity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern. This was revealed in a recent tour-de-force research study currently available on the bioRxiv* preprint server while the article undergoes the peer review process.

11 Jul 2021

Pfizer aims to implement boosters and a new vaccine based on SARS-CoV-2 Delta variant

The drugmaker Pfizer, one of the companies behind the Pfizer-BioNTech vaccine, or BNT162b2, awaits the green light to develop a COVID-19 booster shot that can protect against emerging variants. Pfizer’s COVID-19 vaccine has been shown to be 95% effective in an ongoing large-scale clinical trial against the original SARS-CoV-2 strain.

11 Jul 2021

Pfizer-BioNTech’s COVID-19 vaccine effective and safe for use among cancer patients

Researchers in Israel have conducted a study showing that the use of Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine appears to be safe and effective among patients with cancer.

11 Jul 2021

Novel monoclonal antibody could pave way for future COVID-19 treatments and vaccines

Researchers in the United States have shown that targeting the N-terminal domain (NTD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral spike protein could achieve broad neutralization of variants of concern.

11 Jul 2021

SARS-CoV-2 immunity due to prior infection or vaccination is similar, study says

A new study finds that the rate of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection is low following one episode of the infection.

11 Jul 2021

Antigen testing identifies PCR-positive children with live SARS-CoV-2

A recent study finds that antigen-based testing can reliably identify children who are infectious for SARS-CoV-2.

11 Jul 2021

Initial SARS-CoV-2 vaccination response may predict BNT162b2 booster response, but not AZD1222

A new study finds that the antibody titer values prior to the booster dose of the BNT162b2 vaccine can predict the final antibody response after two doses.

11 Jul 2021

Study examines SARS-CoV-2's inactivation across a range of UVC wavelengths

A recent study published on the preprint server medRxiv* describes the disinfection of SARS-CoV-2 using UVC irradiation at different wavelengths.

11 Jul 2021

Can saliva metabolomics predict COVID-19 severity?

New research suggests that saliva metabolomics may be able to help prognosticate disease severity in COVID-19 positive individuals.

9 Jul 2021

Antiviral activity of long-chain polyphosphates against SARS-CoV-2 infection

A new study has been published in Science Signaling that has examined the potential role that long-chain inorganic polyphosphates (polyPs) play against SARS-CoV-2 infection.

9 Jul 2021

New York City SARS-CoV-2 breakthrough cases predominantly Alpha and Iota variants

While Delta (B.1.617.2) has overtaken Alpha (B.1.1.7) as the dominant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant in the United States, Alpha remained a force to be reckoned with in New York City earlier this year. New research published on the preprint medRxiv* server details breakthrough infections in vaccinated and unvaccinated individuals living in New York City.

9 Jul 2021

Researchers model probability of extinction of SARS-CoV-2 variant in an outbreak

However, it cannot be confirmed for certain that the strain has been eliminated, raising the question of how long a strain must go undetected before being considered, in all probability, extinct.

9 Jul 2021

Durable antibody response at least 8 months following vaccination with J&J COVID vaccine

A recent study by a team of scientists at Beth Israel Deaconess Medical Center and Janssen Vaccines & Prevention has demonstrated that humoral and cellular immunity elicited by the coronavirus disease 2019 (COVID-19) vaccine Ad26.COV2.S remains active for at least eight months.

9 Jul 2021

Why is the SARS-CoV-2 Delta variant so concerning?

As cases surge in the United States, health experts have raised the alarm that vaccinated individuals may be spreading the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant. Over half of new infections in the U.S. are now caused by this highly transmissible variant.

9 Jul 2021

SARS-CoV-2 antibody testing in oral fluids may be an efficient way forward for research in children

A recent study by researchers from the United Kingdom (UK) and Brazil shows how laboratory assays based on the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in oral fluids can be used as a suitable tool for population-based seroepidemiology studies in children. The paper is currently available on the medRxiv* preprint server while it undergoes peer review.

8 Jul 2021

Breakthrough SARS-CoV-2 infection among fully vaccinated likely to be less transmissible

Researchers in the United States have conducted a study suggesting that individuals fully vaccinated against coronavirus disease 2019 (COVID-19) who develop breakthrough infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are less likely to transmit the virus to others than unvaccinated infected individuals.

8 Jul 2021

Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Composition and structure of nasopharyngeal microbiome relate to COVID-19 disease severity

What is behind the inconsistent results of COVID-19 clinical trials?

SARS-CoV-2 mRNA vaccine efficacy reduced in patients with CD20-B-cell depleting treatment history

Socioeconomic inequities and structural racism are neglected pieces of SARS-CoV-2 transmission networks

Accelerating the design of minibinder therapeutics resilient to SARS-CoV-2 mutations

Pfizer aims to implement boosters and a new vaccine based on SARS-CoV-2 Delta variant

Pfizer-BioNTech’s COVID-19 vaccine effective and safe for use among cancer patients

Novel monoclonal antibody could pave way for future COVID-19 treatments and vaccines

SARS-CoV-2 immunity due to prior infection or vaccination is similar, study says

Antigen testing identifies PCR-positive children with live SARS-CoV-2

Initial SARS-CoV-2 vaccination response may predict BNT162b2 booster response, but not AZD1222

Study examines SARS-CoV-2's inactivation across a range of UVC wavelengths

Can saliva metabolomics predict COVID-19 severity?

Antiviral activity of long-chain polyphosphates against SARS-CoV-2 infection

New York City SARS-CoV-2 breakthrough cases predominantly Alpha and Iota variants

Researchers model probability of extinction of SARS-CoV-2 variant in an outbreak

Durable antibody response at least 8 months following vaccination with J&J COVID vaccine

Why is the SARS-CoV-2 Delta variant so concerning?

SARS-CoV-2 antibody testing in oral fluids may be an efficient way forward for research in children

Breakthrough SARS-CoV-2 infection among fully vaccinated likely to be less transmissible

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in